Cancer virotherapy: Targeting cancer cells by microRNA mechanism for selective replication of oncolytic viruses in these cells

Authors

  • Kakavandi, Ehsan Dept. of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran-Students’ Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran
  • Moghim , Sharareh Dept. of Bacteriology and Virology, Faculty of Medicine, Isfahan University of Medical Science, Isfahan, Iran
  • Shayestehpour, Mohammad Dept. of Microbiology and Immunology, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran-Autoimmune Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran
Abstract:

Cancer, as one of the most serious public health problems, is the second-leading cause of death in the world after cardiovascular disease. The number of patients and the resulting mortality are increasing worldwide; therefore, early diagnosis, prevention, and effective treatment of cancer are very important. Current treatments such as chemotherapy and radiation therapy are often non-selective and have side effects. The use of oncolytic viruses (viral therapy) is a new approach to treating cancer. One problem with viral therapy is the lack of selective replication for the virus in cancer cells, meaning that the virus replicates in normal cells. In recent years, various methods have been used to inhibit virus replication in healthy cells and to make selective replication in tumors. Correspondingly, MiRNA targeting is the newest method. The present review article describes the different aspects of making selectivity for replication of oncolytic viruses by the miRNA targeting mechanism

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Oncolytic Virotherapy in Cancer

Oncolytic viruses are natural or genetically modified viral species that selectively infect and kill neoplastic cells. Oncolytic viruses as highly targeted agents that would mediate cancer cell-autonomous anticancer effects. The therapeutic potential of oncolytic virotherapy is not a simple consequence of the cytopathic effect, but strongly relies on the induction of an endogenous immune respon...

full text

Oncolytic virotherapy for ovarian cancer

In the past two decades, more than 20 viruses with selective tropism for tumor cells have been developed as oncolytic viruses (OVs) for treatments of a variety of malignancies. Of these viruses, eleven have been tested in human ovarian cancer models in preclinical studies. So far, nine phase I or II clinical trials have been conducted or initiated using four different types of OVs in patients w...

full text

CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells.

Signals mediated by the chemokine CXCL12 and its receptor CXCR4 are involved in the progression of ovarian cancer through enhancement of tumor angiogenesis and immunosuppressive networks that regulate dissemination of peritoneal metastasis and development of cancer-initiating cells (CICs). In this study, we investigated the antitumor efficacy of a CXCR4 antagonist expressed by oncolytic vaccini...

full text

Targeting Cancer-Initiating Cells Growth by Decreasing Immunosuppression Virotherapy Inhibits Ovarian Cancer CXCL12/CXCR4 Blockade by Oncolytic

full text

Oncolytic virotherapy of ovarian cancer

full text

Oncolytic viral therapy: targeting cancer stem cells

Cancer stem cells (CSCs) are defined as rare populations of tumor-initiating cancer cells that are capable of both self-renewal and differentiation. Extensive research is currently underway to develop therapeutics that target CSCs for cancer therapy, due to their critical role in tumorigenesis, as well as their resistance to chemotherapy and radiotherapy. To this end, oncolytic viruses targetin...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 24  issue 3

pages  288- 299

publication date 2022-05

{@ msg @}

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

No Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023